OBJECTIVE: To assess the relative cost effectiveness of clinical nurse specialist care, inpatient team care, and day patient team care. METHODS: Incremental cost effectiveness analysis and cost utility analysis, alongside a prospective randomised controlled trial with two year follow up. Included were patients with rheumatoid arthritis (RA) with increasing difficulty in performing activities of daily living over the previous six weeks. Quality of life and utility were assessed by the Rheumatoid Arthritis Quality of Life questionnaire, the Short Form-6D, a transformed rating scale, and the time tradeoff. A cost-price analysis was conducted to estimate the costs of inpatient and day patient hospitalisations. Other healthcare and non-healthcare costs were estimated from cost questionnaires. RESULTS:210 patients with RA (75% female, median age 59 years) were included. Aggregated over the two year follow up period, no significant differences were found on the quality of life and utility instruments. The costs of the initial treatment were estimated at euro 200 for clinical nurse specialist care, euro 5000 for inpatient team care, and euro 4100 for day patient team care. Other healthcare costs and non-healthcare costs were not significantly different. The total societal costs did not differ significantly between inpatients and day patients, but were significantly lower for the clinical nurse specialist patients by at least euro 5400. CONCLUSIONS: Compared with inpatient and day patient team care, clinical nurse specialist care was shown to provide equivalent quality of life and utility, at lower costs. Therefore, for patients with health conditions that allow for any of the three types of care, the preferred treatment from a health-economic perspective is the care provided by the clinical nurse specialist.
RCT Entities:
OBJECTIVE: To assess the relative cost effectiveness of clinical nurse specialist care, inpatient team care, and day patient team care. METHODS: Incremental cost effectiveness analysis and cost utility analysis, alongside a prospective randomised controlled trial with two year follow up. Included were patients with rheumatoid arthritis (RA) with increasing difficulty in performing activities of daily living over the previous six weeks. Quality of life and utility were assessed by the Rheumatoid Arthritis Quality of Life questionnaire, the Short Form-6D, a transformed rating scale, and the time tradeoff. A cost-price analysis was conducted to estimate the costs of inpatient and day patient hospitalisations. Other healthcare and non-healthcare costs were estimated from cost questionnaires. RESULTS: 210 patients with RA (75% female, median age 59 years) were included. Aggregated over the two year follow up period, no significant differences were found on the quality of life and utility instruments. The costs of the initial treatment were estimated at euro 200 for clinical nurse specialist care, euro 5000 for inpatient team care, and euro 4100 for day patient team care. Other healthcare costs and non-healthcare costs were not significantly different. The total societal costs did not differ significantly between inpatients and day patients, but were significantly lower for the clinical nurse specialist patients by at least euro 5400. CONCLUSIONS: Compared with inpatient and day patient team care, clinical nurse specialist care was shown to provide equivalent quality of life and utility, at lower costs. Therefore, for patients with health conditions that allow for any of the three types of care, the preferred treatment from a health-economic perspective is the care provided by the clinical nurse specialist.
Authors: G J Tijhuis; S J Jansen; A M Stiggelbout; A H Zwinderman; J M Hazes; T P Vliet Vlieland Journal: Ann Rheum Dis Date: 2000-11 Impact factor: 19.103
Authors: Santiago Muñoz-Fernández; Ma Dolores Aguilar; Amparo Rodríguez; Raquel Almodóvar; Laura Cano-García; Luís Antonio Gracia; José A Román-Ivorra; J Ramón Rodríguez; Teresa Navío; Pablo Lázaro Journal: Rheumatol Int Date: 2016-07-19 Impact factor: 2.631
Authors: Santiago Muñoz-Fernández; Ma Dolores Aguilar; Raquel Almodóvar; Laura Cano-García; Sandra Fortea; Cristina Patricia Alcañiz-Escandell; José R Rodríguez; Laura Cebrián; Pablo Lázaro Journal: Rheumatol Int Date: 2017-01-20 Impact factor: 2.631
Authors: Linda Mary Davies; Emily Anne Fargher; Karen Tricker; Peter Dawes; David L Scott; Deborah Symmons Journal: Ann Rheum Dis Date: 2006-11-23 Impact factor: 19.103
Authors: Manjari Lahiri; Peter P M Cheung; Preeti Dhanasekaran; Su-Ren Wong; Ai Yap; Daphne S H Tan; Siew-Hwa Chong; Chiew-Hwa Tan; Amelia Santosa; Phillip Phan Journal: Qual Life Res Date: 2021-11-06 Impact factor: 4.147
Authors: Veronique M A Voorn; Henricus M Vermeulen; Rob G H H Nelissen; Margreet Kloppenburg; Tom W J Huizinga; Nicolette A C Leijerzapf; Herman M Kroon; Thea P M Vliet Vlieland; Henrica M J van der Linden Journal: Rheumatol Int Date: 2013-01-17 Impact factor: 2.631